AU2009243813B2 - Method for treating cognitive deficits - Google Patents
Method for treating cognitive deficits Download PDFInfo
- Publication number
- AU2009243813B2 AU2009243813B2 AU2009243813A AU2009243813A AU2009243813B2 AU 2009243813 B2 AU2009243813 B2 AU 2009243813B2 AU 2009243813 A AU2009243813 A AU 2009243813A AU 2009243813 A AU2009243813 A AU 2009243813A AU 2009243813 B2 AU2009243813 B2 AU 2009243813B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- cognitive
- salt
- phenylindan
- trimethylpiperazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title abstract description 46
- 230000007278 cognition impairment Effects 0.000 title description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 54
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 52
- 238000011282 treatment Methods 0.000 claims description 51
- 201000000980 schizophrenia Diseases 0.000 claims description 47
- 208000028698 Cognitive impairment Diseases 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims description 9
- 150000002690 malonic acid derivatives Chemical class 0.000 claims description 8
- 230000000698 schizophrenic effect Effects 0.000 claims description 4
- 150000003890 succinate salts Chemical class 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 56
- 239000011230 binding agent Substances 0.000 abstract description 22
- 230000001149 cognitive effect Effects 0.000 abstract description 13
- BYPMJBXPNZMNQD-PZJWPPBQSA-N Zicronapine Chemical compound C1C(C)(C)N(C)CCN1[C@H]1C2=CC(Cl)=CC=C2[C@H](C=2C=CC=CC=2)C1 BYPMJBXPNZMNQD-PZJWPPBQSA-N 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 description 159
- 239000003826 tablet Substances 0.000 description 73
- 241000700159 Rattus Species 0.000 description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 47
- 201000010099 disease Diseases 0.000 description 33
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 33
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 32
- 230000006735 deficit Effects 0.000 description 27
- 230000000694 effects Effects 0.000 description 27
- 238000012360 testing method Methods 0.000 description 25
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000007941 film coated tablet Substances 0.000 description 18
- 230000006870 function Effects 0.000 description 18
- 229920001531 copovidone Polymers 0.000 description 17
- 208000028017 Psychotic disease Diseases 0.000 description 16
- 235000019359 magnesium stearate Nutrition 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 14
- 230000015654 memory Effects 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 229920002261 Corn starch Polymers 0.000 description 12
- 101150049660 DRD2 gene Proteins 0.000 description 12
- 230000019771 cognition Effects 0.000 description 12
- 239000000314 lubricant Substances 0.000 description 11
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 11
- 239000000454 talc Substances 0.000 description 11
- 235000012222 talc Nutrition 0.000 description 11
- 229910052623 talc Inorganic materials 0.000 description 11
- 229920002785 Croscarmellose sodium Polymers 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
- 235000019759 Maize starch Nutrition 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000008101 lactose Substances 0.000 description 10
- 230000013016 learning Effects 0.000 description 10
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 9
- 230000003935 attention Effects 0.000 description 9
- 229960004170 clozapine Drugs 0.000 description 9
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 9
- 229960001681 croscarmellose sodium Drugs 0.000 description 9
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000010326 executive functioning Effects 0.000 description 9
- 239000000945 filler Substances 0.000 description 9
- 229940033134 talc Drugs 0.000 description 9
- 230000031836 visual learning Effects 0.000 description 9
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 239000012458 free base Substances 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000004408 titanium dioxide Substances 0.000 description 8
- 229920002774 Maltodextrin Polymers 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 239000007916 tablet composition Substances 0.000 description 7
- -1 theophylline acetic acids Chemical class 0.000 description 7
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 6
- 239000005913 Maltodextrin Substances 0.000 description 6
- 238000000540 analysis of variance Methods 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 239000007888 film coating Substances 0.000 description 6
- 238000009501 film coating Methods 0.000 description 6
- 238000005469 granulation Methods 0.000 description 6
- 230000003179 granulation Effects 0.000 description 6
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 229940035034 maltodextrin Drugs 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 108091005435 5-HT6 receptors Proteins 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000000164 antipsychotic agent Substances 0.000 description 5
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 5
- 230000037411 cognitive enhancing Effects 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 235000019700 dicalcium phosphate Nutrition 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 229960003943 hypromellose Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000006742 locomotor activity Effects 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 235000019645 odor Nutrition 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 238000004886 process control Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000009151 sensory gating Effects 0.000 description 5
- 201000009032 substance abuse Diseases 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 208000020925 Bipolar disease Diseases 0.000 description 4
- 208000011597 CGF1 Diseases 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 229940069328 povidone Drugs 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000004039 social cognition Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 230000001755 vocal effect Effects 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- 208000007848 Alcoholism Diseases 0.000 description 3
- 208000024254 Delusional disease Diseases 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- 206010026749 Mania Diseases 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- 208000020186 Schizophreniform disease Diseases 0.000 description 3
- 208000019568 Shared Paranoid disease Diseases 0.000 description 3
- 208000028810 Shared psychotic disease Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010043903 Tobacco abuse Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 206010001584 alcohol abuse Diseases 0.000 description 3
- 208000025746 alcohol use disease Diseases 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 239000003176 neuroleptic agent Substances 0.000 description 3
- 230000000701 neuroleptic effect Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 208000002851 paranoid schizophrenia Diseases 0.000 description 3
- 238000011170 pharmaceutical development Methods 0.000 description 3
- 229950010883 phencyclidine Drugs 0.000 description 3
- 238000002600 positron emission tomography Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 208000022610 schizoaffective disease Diseases 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 208000022925 sleep disturbance Diseases 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940124801 5-HT6 antagonist Drugs 0.000 description 2
- 208000017194 Affective disease Diseases 0.000 description 2
- 208000021465 Brief psychotic disease Diseases 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 206010013496 Disturbance in attention Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000011963 Substance-induced psychotic disease Diseases 0.000 description 2
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000004793 poor memory Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000002637 putamen Anatomy 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 230000003936 working memory Effects 0.000 description 2
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- FGHVSEXHEAUJBT-HFNHQGOYSA-N (z)-but-2-enedioic acid;(5r)-8-chloro-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound OC(=O)\C=C/C(O)=O.C1([C@@H]2C3=CC(O)=C(Cl)C=C3CCN(C2)C)=CC=CC=C1 FGHVSEXHEAUJBT-HFNHQGOYSA-N 0.000 description 1
- RFAPOGMFZTYBEW-UHFFFAOYSA-N 1,2,2-trimethylpiperazine Chemical compound CN1CCNCC1(C)C RFAPOGMFZTYBEW-UHFFFAOYSA-N 0.000 description 1
- UEWDNBBZGQGYEW-UHFFFAOYSA-N 1-[2-[4-[5-fluoro-1-(4-fluorophenyl)indol-3-yl]piperidin-1-yl]ethyl]imidazolidin-2-one Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(F)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 UEWDNBBZGQGYEW-UHFFFAOYSA-N 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010005885 Blunted affect Diseases 0.000 description 1
- 208000022497 Cocaine-Related disease Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 108090000511 Dopamine D1 Receptors Proteins 0.000 description 1
- 101100066896 Drosophila melanogaster cher gene Proteins 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000964051 Homo sapiens 5-hydroxytryptamine receptor 6 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZAGRKAFMISFKIO-UHFFFAOYSA-N Isolysergic acid Natural products C1=CC(C2=CC(CN(C2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940124604 anti-psychotic medication Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000001272 cocaine abuse Diseases 0.000 description 1
- 230000037410 cognitive enhancement Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002706 dry binder Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical compound C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013289 male long evans rat Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 108010022888 neurotensin 69L Proteins 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000003414 procognitive effect Effects 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229950001518 raclopride Drugs 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 210000004894 snout Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200800647 | 2008-05-07 | ||
| DKPA200800647 | 2008-05-07 | ||
| DKPA200801392 | 2008-10-03 | ||
| DKPA200801392 | 2008-10-03 | ||
| DKPA200801519 | 2008-11-04 | ||
| DKPA200801519 | 2008-11-04 | ||
| PCT/DK2009/050107 WO2009135495A1 (en) | 2008-05-07 | 2009-05-07 | Method for treating cognitive deficits |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2009243813A1 AU2009243813A1 (en) | 2009-11-12 |
| AU2009243813B2 true AU2009243813B2 (en) | 2014-05-29 |
Family
ID=40870955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009243813A Ceased AU2009243813B2 (en) | 2008-05-07 | 2009-05-07 | Method for treating cognitive deficits |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20090306092A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2285377A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2011519873A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20110021754A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102065861B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009243813B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0912223A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2722374A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO6311083A2 (cg-RX-API-DMAC7.html) |
| EA (1) | EA018927B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL209084A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010012037A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ589571A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009135495A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201007912B (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2732613A1 (en) * | 2008-10-03 | 2010-04-08 | H. Lundbeck A/S | Oral formulation |
| TWI552751B (zh) * | 2011-06-20 | 2016-10-11 | Ｈ 朗德貝克公司 | 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法 |
| HUE030883T2 (en) | 2011-06-20 | 2017-06-28 | H Lundbeck As | Deuterated 1-piperazino-3-phenylindanes for the treatment of schizophrenia |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| US20210395208A1 (en) * | 2018-10-29 | 2021-12-23 | H. Lundeck A/S | Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts |
| WO2020114853A1 (en) | 2018-12-03 | 2020-06-11 | H. Lundbeck A/S | Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993022293A1 (en) * | 1992-04-28 | 1993-11-11 | H. Lundbeck A/S | 1-piperazino-1,2-dihydroindene derivatives |
| WO2005016900A1 (en) * | 2003-08-18 | 2005-02-24 | H. Lundbeck A/S | Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament |
| WO2006086986A1 (en) * | 2005-02-16 | 2006-08-24 | H. Lundbeck A/S | Crystalline base of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
| WO2006086985A1 (en) * | 2005-02-16 | 2006-08-24 | H. Lundbeck A/S | Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4031216A (en) * | 1974-08-12 | 1977-06-21 | Knoll A.G. Chemische Fabriken | 3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines |
| IE50867B1 (en) * | 1980-02-29 | 1986-08-06 | Kefalas As | Indane derivatives |
| DE3139970A1 (de) * | 1981-10-08 | 1983-04-28 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
| US5026853A (en) * | 1987-04-01 | 1991-06-25 | Janssen Pharmaceutica N.V. | 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide |
| US5466806A (en) * | 1989-02-08 | 1995-11-14 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
| CA2091204C (en) * | 1992-03-11 | 1997-04-08 | Ronald J. Mattson | Antiischemic-piperazinyl and piperidinyl-cyclohexanes |
| CA2132411A1 (en) * | 1994-09-19 | 1996-03-20 | Michael Trani | Enzymatic esterification of long-chain racemic acids and alcohols |
| US6410794B1 (en) * | 1994-12-16 | 2002-06-25 | Uop Llc | Process for preparation of pharmaceutically desired chiral tetralone from tetralones |
| US6455736B1 (en) * | 1994-12-16 | 2002-09-24 | Uop Llc | Process for preparation of pharmaceutically desired sertraline and sertraline analogs |
| US5807897A (en) * | 1996-03-01 | 1998-09-15 | Zeneca Limited | Aminotetralin derivative and compositions and method of use thereof |
| DK1073618T3 (da) * | 1998-05-01 | 2004-03-15 | Pfizer Prod Inc | Fremgangsmåde til fremstilling af enantiomerisk ren eller optisk beriget sertralin-tetralon under anvendelse af kontinuerlig kromatografi |
| DE19824470A1 (de) * | 1998-05-30 | 1999-12-02 | Boehringer Ingelheim Pharma | Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| FR2786769B1 (fr) * | 1998-12-04 | 2002-10-25 | Synthelabo | Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique |
| IN187170B (cg-RX-API-DMAC7.html) * | 2000-01-04 | 2002-02-23 | Sun Pharmaceutical Ind Ltd | |
| WO2003057151A2 (en) * | 2001-12-28 | 2003-07-17 | Teva Pharmaceutical Industries Ltd. | A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof |
| WO2004039322A2 (en) * | 2002-10-29 | 2004-05-13 | Miicro, Inc. | Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake |
| TW200640891A (en) * | 2005-02-16 | 2006-12-01 | Lundbeck & Co As H | Tartrate and malate salts of a pharmarceutical compound |
| TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| CA2732613A1 (en) * | 2008-10-03 | 2010-04-08 | H. Lundbeck A/S | Oral formulation |
-
2009
- 2009-05-07 CA CA2722374A patent/CA2722374A1/en not_active Abandoned
- 2009-05-07 NZ NZ589571A patent/NZ589571A/en not_active IP Right Cessation
- 2009-05-07 BR BRPI0912223A patent/BRPI0912223A2/pt not_active IP Right Cessation
- 2009-05-07 JP JP2011507792A patent/JP2011519873A/ja active Pending
- 2009-05-07 EA EA201071273A patent/EA018927B1/ru not_active IP Right Cessation
- 2009-05-07 EP EP09741768A patent/EP2285377A1/en not_active Withdrawn
- 2009-05-07 WO PCT/DK2009/050107 patent/WO2009135495A1/en not_active Ceased
- 2009-05-07 KR KR1020107024956A patent/KR20110021754A/ko not_active Withdrawn
- 2009-05-07 MX MX2010012037A patent/MX2010012037A/es not_active Application Discontinuation
- 2009-05-07 AU AU2009243813A patent/AU2009243813B2/en not_active Ceased
- 2009-05-07 CN CN2009801162104A patent/CN102065861B/zh not_active Expired - Fee Related
- 2009-05-07 US US12/437,363 patent/US20090306092A1/en not_active Abandoned
-
2010
- 2010-11-02 IL IL209084A patent/IL209084A0/en unknown
- 2010-11-04 ZA ZA2010/07912A patent/ZA201007912B/en unknown
- 2010-11-30 CO CO10150622A patent/CO6311083A2/es not_active Application Discontinuation
-
2011
- 2011-05-05 US US13/101,176 patent/US20110207744A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993022293A1 (en) * | 1992-04-28 | 1993-11-11 | H. Lundbeck A/S | 1-piperazino-1,2-dihydroindene derivatives |
| WO2005016900A1 (en) * | 2003-08-18 | 2005-02-24 | H. Lundbeck A/S | Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament |
| WO2006086986A1 (en) * | 2005-02-16 | 2006-08-24 | H. Lundbeck A/S | Crystalline base of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
| WO2006086985A1 (en) * | 2005-02-16 | 2006-08-24 | H. Lundbeck A/S | Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
Non-Patent Citations (1)
| Title |
|---|
| BOGESO, K.P. et al. "Enhanced D1 Affinity in a Series of Piperazine Ring Substituted 1-Piperazino- 3-Arylindans with Potential Atypical Antipsychotic Activity" Journal of Medicinal Chemistry (1995) Vol.38 No.22 pages 4380 to 4392 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EA018927B1 (ru) | 2013-11-29 |
| IL209084A0 (en) | 2011-01-31 |
| US20110207744A1 (en) | 2011-08-25 |
| JP2011519873A (ja) | 2011-07-14 |
| BRPI0912223A2 (pt) | 2015-10-06 |
| CN102065861B (zh) | 2013-10-16 |
| EA201071273A1 (ru) | 2011-06-30 |
| MX2010012037A (es) | 2010-11-30 |
| NZ589571A (en) | 2012-07-27 |
| WO2009135495A1 (en) | 2009-11-12 |
| EP2285377A1 (en) | 2011-02-23 |
| CN102065861A (zh) | 2011-05-18 |
| CO6311083A2 (es) | 2011-08-22 |
| CA2722374A1 (en) | 2009-11-12 |
| ZA201007912B (en) | 2012-02-29 |
| HK1157674A1 (en) | 2012-07-06 |
| AU2009243813A1 (en) | 2009-11-12 |
| KR20110021754A (ko) | 2011-03-04 |
| US20090306092A1 (en) | 2009-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009243813B2 (en) | Method for treating cognitive deficits | |
| Bhana et al. | Olanzapine: an updated review of its use in the management of schizophrenia | |
| JP2012504560A (ja) | 経口製剤 | |
| RS49828B (sr) | Farmaceutski sastavi | |
| Meneses et al. | 5-HT1AReceptors Modulate the Consolidation of Learning in Normal and Cognitively Impaired Rats | |
| Mezler et al. | LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia | |
| JP2023523569A (ja) | 神経学的および精神障害の治療方法 | |
| CA2968977A1 (en) | Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia | |
| CA2478227A1 (en) | Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist | |
| CN107810002A (zh) | 左乙拉西坦的延时释放药物组合物 | |
| WO2021016369A1 (en) | Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder | |
| US20140221385A1 (en) | Combinations of serotonin receptor agonists for treatment of movement disorders | |
| BRPI0715445A2 (pt) | Uso de um composto de bifeprunox, e, kit de titulação | |
| JP2008156297A (ja) | セロトニン２ｂおよび／または２ｃ受容体拮抗剤 | |
| KR20210151162A (ko) | 자폐 범주성 장애를 치료하기 위한 카바모일 사이클로헥산 유도체 | |
| Freudenreich et al. | 7 Antipsychotic Drugs | |
| HK1157674B (en) | Use of trans-4((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine for improving cognition | |
| Maguire | Impact of antipsychotics on geriatric patients: efficacy, dosing, and compliance | |
| CN114761008B (zh) | 用于在患有痴呆的患者中治疗行为和心理症状的方法 | |
| HK40071167A (en) | Methods for treating behavioral and psychological symptoms in patients with dementia | |
| HK40067131B (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder | |
| HK40067131A (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder | |
| Ayd Jr | Tardive dyskinesia: Recent developments | |
| Rappard et al. | P. 3. c. 056 Efficacy of ziprasidone in the treatment of schizoaffective disorder: an analysis of 2 fixed-dose, placebo-controlled trials | |
| Amith | The discriminative stimulus properties of psychotomimetics and antipsychotics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |